Observational studyAnnals of surgical oncology2026
Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy.
Observational study in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Navigating Axillary Management for Residual Nodal Disease after Neoadjuvant Chemotherapy in Breast Cancer.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundFor breast cancer patients with clinically node-positive (cN+) and residual disease after neoadjuvant chemotherapy (NAC), axillary lymph node dissection (ALND) remains the standard of care, though alternative strategies may be selected by multidisciplinary teams in certain cases. This study evaluated factors associated with omission of ALND for cN+ patients who were pathologically node-positive after NAC (ypN+).
methodsIn this retrospective observational study, the National Cancer Database was queried for patients with clinical T1-T4, N1-N3 breast cancer from 2016 to 2021 who received NAC and were subsequently ypN+. Axillary procedures were categorized as sentinel lymph node biopsy (SLNB) alone, SLNB followed by ALND (SLNB + ALND), or ALND alone. Logistic regression identified factors associated with omission of ALND after SLNB, adjusting for sociodemographic, geographic, and clinical variables.
resultsAmong 38,559 patients, axillary interventions were SLNB alone (n = 7,131, 18.49%), SLNB+ALND (n = 14,247, 36.95%), and ALND alone (n = 17,179, 44.55%). Over the study period, SLNB alone and SLNB + ALND increased while ALND alone decreased. Compared with academic programs, patients treated at comprehensive community, integrated network, and community programs had greater odds of SLNB alone compared with SLNB+ALND (odds ratio [OR] 1.32, 95% confidence interval [CI] 1.22-1.43; OR 1.17, 95% CI 1.07-1.27; OR 1.54, 95% CI 1.33-1.78, respectively).
conclusionsThere has been de-escalation of ALND after initial SLNB for cN+ breast cancer patients found to be ypN+. This suggests that providers may be extrapolating evidence supporting SLNB alone to populations in which it has not yet been thoroughly studied or are omitting ALND in anticipation of ongoing clinical trial results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.